Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 47Lung Neoplasms 25Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Colorectal Neoplasms 5Pancreatic Neoplasms 4Mesothelioma, Malignant 3Melanoma 3Colonic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-squamous Non-small Cell Lung Cancer 2Neoplasms by Site 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma 2Adenocarcinoma of Lung 2Vaccinia 1Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1

Interventions

Bevacizumab 19Paclitaxel 16Carboplatin 12pembrolizumab 11liposomal doxorubicin 10Cyclophosphamide 9Specimen Handling 8Gemcitabine 8olaparib 7fludarabine 7Topotecan 7Magnetic Resonance Spectroscopy 7Taxes 5Immunoglobulin G 5Fulvestrant 5Disulfides 5niraparib 4Oxaliplatin 4Nivolumab 4Biopsy 4trastuzumab deruxtecan 3palbociclib 3mirvetuximab soravtansine 3aldesleukin 3Leucovorin 3Fluorouracil 31-dodecylpyridoxal 3ulixertinib 2nilotinib 2ipatasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Pemetrexed × 30 days × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡